Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03148795 · ClinicalTrials.gov registry record · Phase 2
A Study of Talazoparib in Men With DNA Repair Defects and Metastatic Castration-Resistant Prostate Cancer
A Phase 2 study, sponsored by Pfizer.
- Completed
- Registry status
- Phase 2
- Development phase
- 128
- Enrollment target
NCT03148795 is a Phase 2 study that has completed, run by Pfizer. The registered enrollment target is 128 participants.
The verdict
NCT03148795, a Phase 2 study, has completed, sponsored by Pfizer.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 128 participants
- Enrollment target
Study Summary
The purpose of this international, phase 2, open-label, response rate study of talazoparib is to assess the efficacy and safety of talazoparib in men with DNA repair defects metastatic castration-resistant prostate cancer (CRPC) who previously received taxane-based chemotherapy and progressed on at least 1 novel hormonal agent (enzalutamide and/or abiraterone acetate/prednisone).
Interventions
- DRUG Talazoparib
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 128 participants |
| Start Date | 2017-07-04 |
| Est. Completion | 2023-03-31 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03148795
The ClinicalTrials.gov registry entry for NCT03148795 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 128 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Pfizer, which has 1,845 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Talazoparib is the first listed.
NCT03148795 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03148795 about?
NCT03148795 is a clinical study titled "A Study of Talazoparib in Men With DNA Repair Defects and Metastatic Castration-Resistant Prostate Cancer". The purpose of this international, phase 2, open-label, response rate study of talazoparib is to assess the efficacy and safety of talazoparib in men with DNA repair defects metastatic castration-resistant prostate cancer (CRPC) who previously received taxane-based chemotherapy and progressed on at ...
What is the current status of trial NCT03148795?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 128 participants. The study started on 2017-07-04. Estimated completion is 2023-03-31.
What interventions are being tested in trial NCT03148795?
The interventions under investigation include: Talazoparib (DRUG).
Who is sponsoring clinical trial NCT03148795?
This trial is sponsored by Pfizer, which has 1,845 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.